文献速递糖尿病

磺脲类药物与β受体阻滞剂联用与2型糖尿病患者严重低血糖风险:一项基于人群的队列研究

Concomitant Use of Sulfonylureas and β-Blockers and the Risk of Severe Hypoglycemia Among Patients With Type 2 Diabetes: A Population-Based Cohort Study.
PubMed 文献 · Diabetes Care · 2023-01-01

基于英国临床实践研究数据链Aurum,纳入1998至2020年启动磺脲类治疗的252,869例患者,采用时间依赖性Cox模型评估磺脲类联合β受体阻滞剂与单用磺脲类相比的严重低血糖风险。结果显示联合使用与严重低血糖风险升高相关(HR 1.53;95%CI 1.42-1.65),β受体阻滞剂的心脏选择性未见显著影响(HR 0.95;95%CI 0.74-1.24)。

要点

  • 磺脲类联合β受体阻滞剂较单用磺脲类严重低血糖风险升高(HR 1.53;95%CI 1.42-1.65)。
  • 非心脏选择性与心脏选择性β受体阻滞剂联用磺脲类的风险无显著差异(HR 0.95;95%CI 0.74-1.24)。
  • 粗发病率严重低血糖为7.8/1000人年,中位随访7.9年。

核心结论

  • β受体阻滞剂与磺脲类联用可能进一步增加严重低血糖风险。
  • β受体阻滞剂的心脏选择性在此关联中似乎未起主要作用。

研究设计与样本

  • 基于人群的队列研究,使用英国临床实践研究数据链Aurum。
  • 纳入1998至2020年启动磺脲类治疗的患者,排除过去6个月内使用β受体阻滞剂者。
  • 共纳入252,869例磺脲类启动者,平均年龄61.3岁,女性占43%,中位随访7.9年。
  • 采用时间依赖性Cox模型估计严重低血糖的风险比(HR)及95%CI,调整基线混杂因素。

主要发现

  • 严重低血糖(因低血糖住院或死亡;ICD-10编码E16.0、E16.1、E16.2)的粗发病率为7.8/1000人年。
  • 当前联合使用磺脲类和β受体阻滞剂与当前单用磺脲类相比,严重低血糖风险升高(HR 1.53;95%CI 1.42-1.65)。
  • 当前联合使用磺脲类和非心脏选择性β受体阻滞剂与联合使用磺脲类和心脏选择性β受体阻滞剂相比,风险无差异(HR 0.95;95%CI 0.74-1.24)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The hypoglycemic potential of β-blockers among users of sulfonylureas, drugs that strongly increase the risk of this potentially fatal adverse effect, is not well understood. Our population-based cohort study assessed the potential association between concomitant use of sulfonylureas and β-blockers versus use of sulfonylureas alone and the risk of severe hypoglycemia. RESEARCH DESIGN AND METHODS: Using the U.K. Clinical Practice Research Datalink Aurum, we included patients initiating sulfonylureas between 1998 and 2020, excluding those with β-blocker use in the past 6 months. Time-dependent Cox models estimated hazard ratios (HRs) with 95% CIs of severe hypoglycemia (hospitalization with or death resulting from hypoglycemia; ICD-10 codes E16.0, E16.1, and E16.2) associated with current concomitant use of sulfonylureas and β-blockers compared with current sulfonylurea use alone, adjusted for baseline confounders. We also compared current concomitant use of sulfonylureas and non-cardioselective versus cardioselective β-blockers. RESULTS: Our cohort included 252,869 initiators of sulfonylureas (mean age 61.3 years; 43% female). Median follow-up was 7.9 years. The crude incidence rate of severe hypoglycemia was 7.8 per 1,000 per year. Concomitant use of sulfonylureas and β-blockers was associated with an increased risk of severe hypoglycemia compared with sulfonylurea use alone (HR 1.53; 95% CI 1.42-1.65). There was no difference in the risk between concomitant use of sulfonylureas and noncardioselective β-blockers and concomitant use of sulfonylureas and cardioselective β-blockers (HR 0.95; 95% CI 0.74-1.24). CONCLUSIONS: β-blockers could further increase the risk of severe hypoglycemia when used concurrently with sulfonylureas. β-blocker cardioselectivity did not seem to play a major role in this regard.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Dimakos J, Cui Y, Platt RW, et al. Concomitant Use of Sulfonylureas and β-Blockers and the Risk of Severe Hypoglycemia Among Patients With Type 2 Diabetes: A Population-Based Cohort Study. Diabetes Care. 2023. PMID: 36525638. doi:10.2337/dc22-1584

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。